Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system

Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontane...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Akiho, Tahara, Kohei, Hane, Yuuki, Matsui, Toshinobu, Sasaoka, Sayaka, Hatahira, Haruna, Motooka, Yumi, Hasegawa, Shiori, Naganuma, Misa, Abe, Junko, Nakao, Satoshi, Takeuchi, Hirofumi, Nakamura, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617225/
https://www.ncbi.nlm.nih.gov/pubmed/28953936
http://dx.doi.org/10.1371/journal.pone.0185654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617225/
https://www.ncbi.nlm.nih.gov/pubmed/28953936
http://dx.doi.org/10.1371/journal.pone.0185654

Ejemplares similares